Monitoring patients taking oral carbonic anhydrase inhibitors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 11004298.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although no prospective studies have been done and no recommendations can be reasonably evidenced based, we believe that our "alternative views" are reason-able, taking into account the serious nature of aplastic anemia and its more favorable prognosis when this disorder is treated early. Because aplastic anemia represents only about one half of possible CAl blood dyscrasias, early recognition of non-aplastic anemia dyscrasias alone Justifies hematologic screening.
Medical subject headings
- Administration, Oral
- Anemia, Aplastic
- Anemia, Aplastic/chemically induced
- Anemia, Aplastic/prevention & control
- Bone Marrow
- Bone Marrow/drug effects
- Carbonic Anhydrase Inhibitors
- Carbonic Anhydrase Inhibitors/adverse effects
- Carbonic Anhydrase Inhibitors/therapeutic use
- Drug Monitoring
- Hematologic Tests
- Humans